Progenics Pharmaceuticals Inc. shares rallied in the extended session Thursday after the cancer drug company said its clinical trial of a prostate cancer imaging agent will continue. Progenics shares surged 13% to $10 after hours. The company said a review of data on its imaging agent to detect prostate cancer, known as 99mTc-MIP-1404, determined that a late-stage clinical study of the agent should continue.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
From:: Stock Market News